Primary graft dysfunction in heart transplantation: the challenge to survival.
Allogreft
Heart transplantation
Management
Primary graft dysfunction
Journal
Journal of cardiothoracic surgery
ISSN: 1749-8090
Titre abrégé: J Cardiothorac Surg
Pays: England
ID NLM: 101265113
Informations de publication
Date de publication:
01 Jun 2024
01 Jun 2024
Historique:
received:
21
03
2024
accepted:
25
05
2024
medline:
2
6
2024
pubmed:
2
6
2024
entrez:
2
6
2024
Statut:
epublish
Résumé
Primary graft dysfunction (PGD) is a life-threatening clinical condition with a high mortality rate, presenting as left, right, or biventricular dysfunction within the initial 24 h following heart transplantation, in the absence of a discernible secondary cause. Given its intricate nature, definitive definition and diagnosis of PGD continues to pose a challenge. The pathophysiology of PGD encompasses numerous underlying mechanisms, some of which remain to be elucidated, including factors like myocardial damage, the release of proinflammatory mediators, and the occurrence of ischemia-reperfusion injury. The dynamic characteristics of both donors and recipients, coupled with the inclination towards marginal lists containing more risk factors, together contribute to the increased incidence of PGD. The augmentation of therapeutic strategies involving mechanical circulatory support accelerates myocardial recovery, thereby significantly contributing to survival. Nonetheless, a universally accepted treatment algorithm for the swift management of this clinical condition, which necessitates immediate intervention upon diagnosis, remains absent. This paper aims to review the existing literature and shed light on how diagnosis, pathophysiology, risk factors, treatment, and perioperative management affect the outcome of PGD.
Identifiants
pubmed: 38824545
doi: 10.1186/s13019-024-02816-6
pii: 10.1186/s13019-024-02816-6
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
313Subventions
Organisme : National Heart, Lung and Blood Institute of the National Institutes of Health
ID : R01HL166140 and R01HL164416
Informations de copyright
© 2024. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
Références
Lund LH, Khush KK, Cherikh WS, Goldfarb S, Kucheryavaya AY, Levvey BJ, et al. The Registry of the International Society for Heart and Lung Transplantation: thirty-fourth adult heart transplantation Report-2017; focus theme: allograft ischemic time. J Heart lung Transplantation: Official Publication Int Soc Heart Transplantation. 2017;36(10):1037–46.
doi: 10.1016/j.healun.2017.07.019
Lund LH, Edwards LB, Kucheryavaya AY, Dipchand AI, Benden C, Christie JD, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirtieth Official Adult Heart Transplant Report–2013; focus theme: age. J Heart lung Transplantation: Official Publication Int Soc Heart Transplantation. 2013;32(10):951–64.
doi: 10.1016/j.healun.2013.08.006
Kobashigawa J, Zuckermann A, Macdonald P, Leprince P, Esmailian F, Luu M, et al. Report from a consensus conference on primary graft dysfunction after cardiac transplantation. J Heart lung Transplantation: Official Publication Int Soc Heart Transplantation. 2014;33(4):327–40.
doi: 10.1016/j.healun.2014.02.027
D’Ancona G, Santise G, Falletta C, Pirone F, Sciacca S, Turrisi M, et al. Primary graft failure after heart transplantation: the importance of donor pharmacological management. Transpl Proc. 2010;42(3):710–2.
doi: 10.1016/j.transproceed.2010.03.027
Listijono DR, Watson A, Pye R, Keogh AM, Kotlyar E, Spratt P, et al. Usefulness of extracorporeal membrane oxygenation for early cardiac allograft dysfunction. J Heart lung Transplantation: Official Publication Int Soc Heart Transplantation. 2011;30(7):783–9.
doi: 10.1016/j.healun.2011.01.728
Avtaar Singh SS, Banner NR, Rushton S, Simon AR, Berry C, Al-Attar N. ISHLT primary graft dysfunction incidence, risk factors, and outcome: a UK National Study. Transplantation. 2019;103(2):336–43.
doi: 10.1097/TP.0000000000002220
pubmed: 29757910
Rhee Y, Kim HJ, Kim JJ, Kim MS, Lee SE, Yun TJ, et al. Primary graft dysfunction after isolated heart transplantation - incidence, risk factors, and clinical implications based on a single-center experience. Circulation Journal: Official J Japanese Circulation Soc. 2021;85(9):1451–9.
doi: 10.1253/circj.CJ-20-0960
Iyer A, Kumarasinghe G, Hicks M, Watson A, Gao L, Doyle A, et al. Primary graft failure after heart transplantation. J Transplantation. 2011;2011:175768.
doi: 10.1155/2011/175768
D’Alessandro C, Aubert S, Golmard JL, Praschker BL, Luyt CE, Pavie A, et al. Extra-corporeal membrane oxygenation temporary support for early graft failure after cardiac transplantation. Eur J cardio-thoracic Surgery: Official J Eur Association Cardio-thoracic Surg. 2010;37(2):343–9.
Dronavalli VB, Rogers CA, Banner NR. Primary cardiac allograft dysfunction-validation of a clinical definition. Transplantation. 2015;99(9):1919–25.
doi: 10.1097/TP.0000000000000620
pubmed: 25742423
pmcid: 4548546
Sabatino M, Vitale G, Manfredini V, Masetti M, Borgese L, Maria Raffa G, et al. Clinical relevance of the International Society for Heart and Lung Transplantation consensus classification of primary graft dysfunction after heart transplantation: Epidemiology, risk factors, and outcomes. J Heart lung Transplantation: Official Publication Int Soc Heart Transplantation. 2017;36(11):1217–25.
doi: 10.1016/j.healun.2017.02.014
Foroutan F, Alba AC, Stein M, Krakovsky J, Chien KGW, Chih S, et al. Validation of the International Society for Heart and Lung Transplantation primary graft dysfunction instrument in heart transplantation. J Heart lung Transplantation: Official Publication Int Soc Heart Transplantation. 2019;38(3):260–6.
doi: 10.1016/j.healun.2018.12.007
Nicoara A, Ruffin D, Cooter M, Patel CB, Thompson A, Schroder JN, et al. Primary graft dysfunction after heart transplantation: incidence, trends, and associated risk factors. Am J Transplantation: Official J Am Soc Transplantation Am Soc Transpl Surg. 2018;18(6):1461–70.
doi: 10.1111/ajt.14588
Moayedi Y, Truby LK, Foroutan F, Han J, Guzman J, Angleitner P, Sabatino M, Felius J, VAN Zyl JS, Rodenas-Alesina E, Fan CP, Devore AD, Miller R, Potena L, Zuckermann A, Farrero M, Chih S, Farr M, Hall S, Ross HJ, Khush KK. The International Consortium on Primary Graft Dysfunction: Redefining Clinical Risk Factors in the Contemporary Era of Heart Transplantation. J Card Fail. 2023 Oct 30:S1071-9164(23)00382-2. https://doi.org/10.1016/j.cardfail.2023.09.018 .
Kaveevorayan P, Tokavanich N, Kittipibul V, Lertsuttimetta T, Singhatanadgige S, Ongcharit P, Sinphurmsukskul S, Ariyachaipanich A, Siwamogsatham S, Thammanatsakul K, Sritangsirikul S, Puwanant S. Primary isolated right ventricular failure after heart transplantation: prevalence, right ventricular characteristics, and outcomes. Sci Rep. 2023;13(1):394. https://doi.org/10.1038/s41598-023-27482-x . PMID: 36624245; PMCID: PMC9829713.
doi: 10.1038/s41598-023-27482-x
pubmed: 36624245
pmcid: 9829713
Smith M. Physiologic changes during brain stem death–lessons for management of the organ donor. J Heart lung Transplantation: Official Publication Int Soc Heart Transplantation. 2004;23(9 Suppl):S217–22.
doi: 10.1016/j.healun.2004.06.017
Dictus C, Vienenkoetter B, Esmaeilzadeh M, Unterberg A, Ahmadi R. Critical care management of potential organ donors: our current standard. Clin Transplant. 2009;23(Suppl 21):2–9.
doi: 10.1111/j.1399-0012.2009.01102.x
pubmed: 19930309
Shivalkar B, Van Loon J, Wieland W, Tjandra-Maga TB, Borgers M, Plets C, et al. Variable effects of explosive or gradual increase of intracranial pressure on myocardial structure and function. Circulation. 1993;87(1):230–9.
doi: 10.1161/01.CIR.87.1.230
pubmed: 8419012
Souter MJ, Eidbo E, Findlay JY, Lebovitz DJ, Moguilevitch M, Neidlinger NA, et al. Organ Donor Management: part 1. Toward a Consensus to Guide Anesthesia services during Donation after Brain Death. Semin Cardiothorac Vasc Anesth. 2018;22(2):211–22.
doi: 10.1177/1089253217749053
pubmed: 29276852
Rosendale JD, Kauffman HM, McBride MA, Chabalewski FL, Zaroff JG, Garrity ER, et al. Hormonal resuscitation yields more transplanted hearts, with improved early function. Transplantation. 2003;75(8):1336–41.
doi: 10.1097/01.TP.0000062839.58826.6D
pubmed: 12717226
Belzer FO, Southard JH. Principles of solid-organ preservation by cold storage. Transplantation. 1988;45(4):673–6.
doi: 10.1097/00007890-198804000-00001
pubmed: 3282347
Marasco SF, Kras A, Schulberg E, Vale M, Lee GA. Impact of warm ischemia time on survival after heart transplantation. Transpl Proc. 2012;44(5):1385–9.
Marelli D, Laks H, Fazio D, Moore S, Moriguchi J, Kobashigawa J. The use of donor hearts with left ventricular hypertrophy. J Heart lung Transplantation: Official Publication Int Soc Heart Transplantation. 2000;19(5):496–503.
doi: 10.1016/S1053-2498(00)00076-0
Anaya-Prado R, Delgado-Vázquez JA. Scientific basis of organ preservation. Curr Opin Organ Transplant. 2008;13(2):129–34.
doi: 10.1097/MOT.0b013e3282f6390a
pubmed: 18685292
D’Alessandro D, Schroder J, Meyer DM, Vidic A, Shudo Y, Silvestry S, Leacche M, Sciortino CM, Rodrigo ME, Pham SM, Copeland H, Jacobs JP, Kawabori M, Takeda K, Zuckermann A. Impact of controlled hypothermic preservation on outcomes following heart transplantation. J Heart Lung Transpl 2024 Mar 19:S1053–2498(24)01530–4. doi: 10.1016/j.healun.2024.03.010. Epub ahead of print. PMID: 38503386.
Banner NR, Thomas HL, Curnow E, Hussey JC, Rogers CA, Bonser RS. The importance of cold and warm cardiac ischemia for survival after heart transplantation. Transplantation. 2008;86(4):542–7.
doi: 10.1097/TP.0b013e31818149b9
pubmed: 18724223
Braunwald E, Kloner RA. Myocardial reperfusion: a double-edged sword? J Clin Investig. 1985;76(5):1713–9.
doi: 10.1172/JCI112160
pubmed: 4056048
pmcid: 424191
Upadhaya S, Madala S, Baniya R, Subedi SK, Saginala K, Bachuwa G. Impact of cyclosporine a use in the prevention of reperfusion injury in acute myocardial infarction: a meta-analysis. Cardiol J. 2017;24(1):43–50.
doi: 10.5603/CJ.a2016.0091
pubmed: 27734457
Zhang CX, Cheng Y, Liu DZ, Liu M, Cui H, Zhang BL, et al. Mitochondria-targeted cyclosporin A delivery system to treat myocardial ischemia reperfusion injury of rats. J Nanobiotechnol. 2019;17(1):18.
doi: 10.1186/s12951-019-0451-9
Levin RL, Degrange MA, Bruno GF, Del Mazo CD, Taborda DJ, Griotti JJ, et al. Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery. Ann Thorac Surg. 2004;77(2):496–9.
doi: 10.1016/S0003-4975(03)01510-8
pubmed: 14759425
Patarroyo M, Simbaqueba C, Shrestha K, Starling RC, Smedira N, Tang WH, et al. Pre-operative risk factors and clinical outcomes associated with vasoplegia in recipients of orthotopic heart transplantation in the contemporary era. J Heart lung Transplantation: Official Publication Int Soc Heart Transplantation. 2012;31(3):282–7.
doi: 10.1016/j.healun.2011.10.010
Wang Y, Liu H, McKenzie G, Witting PK, Stasch JP, Hahn M, et al. Kynurenine is an endothelium-derived relaxing factor produced during inflammation. Nat Med. 2010;16(3):279–85.
doi: 10.1038/nm.2092
pubmed: 20190767
pmcid: 3556275
Wright M, Takeda K, Mauro C, Jennings D, Kurlansky P, Han J, et al. Dose-dependent association between amiodarone and severe primary graft dysfunction in orthotopic heart transplantation. J Heart lung Transplantation: Official Publication Int Soc Heart Transplantation. 2017;36(11):1226–33.
doi: 10.1016/j.healun.2017.05.025
Cooper LB, Mentz RJ, Edwards LB, Wilk AR, Rogers JG, Patel CB, et al. Amiodarone use in patients listed for heart transplant is associated with increased 1-year post-transplant mortality. J Heart lung Transplantation: Official Publication Int Soc Heart Transplantation. 2017;36(2):202–10.
doi: 10.1016/j.healun.2016.07.009
Cosío Carmena MD, Gómez Bueno M, Almenar L, Delgado JF, Arizón JM, González Vilchez F, et al. Primary graft failure after heart transplantation: characteristics in a contemporary cohort and performance of the RADIAL risk score. J Heart lung Transplantation: Official Publication Int Soc Heart Transplantation. 2013;32(12):1187–95.
doi: 10.1016/j.healun.2013.08.004
Takeda K, Li B, Garan AR, Topkara VK, Han J, Colombo PC, et al. Improved outcomes from extracorporeal membrane oxygenation versus ventricular assist device temporary support of primary graft dysfunction in heart transplant. J Heart lung Transplantation: Official Publication Int Soc Heart Transplantation. 2017;36(6):650–6.
doi: 10.1016/j.healun.2016.12.006
Rastan AJ, Dege A, Mohr M, Doll N, Falk V, Walther T, et al. Early and late outcomes of 517 consecutive adult patients treated with extracorporeal membrane oxygenation for refractory postcardiotomy cardiogenic shock. J Thorac Cardiovasc Surg. 2010;139(2):302–11. 11 e1.
doi: 10.1016/j.jtcvs.2009.10.043
pubmed: 20106393
Olivella A, Almenar-Bonet L, González-Vilchez F, Díez-López C, Díaz-Molina B, Blázquez-Bermejo Z, Sobrino-Márquez JM, Gómez-Bueno M, Garrido-Bravo IP, Barge-Caballero E, Farrero-Torres M, García-Cosio MD, Blasco-Peiró T, Pomares-Varó A, Muñiz J, González-Costello J. Mechanical circulatory support in severe primary graft dysfunction: peripheral cannulation but not earlier implantation improves survival in heart transplantation. J Heart Lung Transpl. 2023;42(8):1101–11. Epub 2023 Mar 15. PMID: 37019730.
doi: 10.1016/j.healun.2023.03.008
Ohira S, Dhand A, Hirani R, Martinez S, Lanier GM, Levine A, Pan S, Aggarwal-Gupta C, Gass AL, Wolfe K, Spielvogel D, Kai M. Cannulation-related adverse events of peripheral veno-arterial extracorporeal membrane oxygenation support in heart transplantation: Axillary versus femoral artery cannulation. Clin Transpl. 2023;37(3):e14871. https://doi.org/10.1111/ctr.14871 . Epub 2022 Dec 18. PMID: 36468757.
doi: 10.1111/ctr.14871
Lorusso R, Whitman G, Milojevic M, Raffa G, McMullan DM, Boeken U, et al. 2020 EACTS/ELSO/STS/AATS expert consensus on post-cardiotomy extracorporeal life support in adult patients. Eur J cardio-thoracic Surgery: Official J Eur Association Cardio-thoracic Surg. 2021;59(1):12–53.
doi: 10.1093/ejcts/ezaa283
Jacob S, Lima B, Gonzalez-Stawinski GV, El-Sayed Ahmed MM, Patel PC, Belli EV, et al. Extracorporeal membrane oxygenation as a salvage therapy for patients with severe primary graft dysfunction after heart transplant. Clin Transplant. 2019;33(5):e13538.
doi: 10.1111/ctr.13538
pubmed: 30870577
DeRoo SC, Takayama H, Nemeth S, Garan AR, Kurlansky P, Restaino S, et al. Extracorporeal membrane oxygenation for primary graft dysfunction after heart transplant. J Thorac Cardiovasc Surg. 2019;158(6):1576–84. e3.
doi: 10.1016/j.jtcvs.2019.02.065
pubmed: 30948318
Lima B, Rajagopal K, Petersen RP, Shah AS, Soule B, Felker GM, et al. Marginal cardiac allografts do not have increased primary graft dysfunction in alternate list transplantation. Circulation. 2006;114(1 Suppl):I27–32.
pubmed: 16820584
Settepani F, Pedrazzini GL, Olivieri GM, Merlanti B, Cannata A, Lanfranconi M, Frigerio M, Russo CF. Long-term effects of primary graft dysfunction after heart transplantation. J Card Surg. 2022;37(5):1290–8. https://doi.org/10.1111/jocs.16364 . Epub 2022 Feb 28. PMID: 35229361.
doi: 10.1111/jocs.16364
pubmed: 35229361
Messer S, Page A, Axell R, Berman M, Hernandez-Sanchez J, Colah S, et al. Outcome after heart transplantation from donation after circulatory-determined death donors. J Heart lung Transplantation: Official Publication Int Soc Heart Transplantation. 2017;36(12):1311–8.
doi: 10.1016/j.healun.2017.10.021
Ayer A, Truby LK, Schroder JN, Casalinova S, Green CL, Bishawi MA, Bryner BS, Milano CA, Patel CB, Devore AD. Improved outcomes in severe primary graft dysfunction after Heart Transplantation following Donation after Circulatory Death compared with Donation after Brain Death. J Card Fail. 2023;29(1):67–75. Epub 2022 Nov 6. PMID: 36351494.
doi: 10.1016/j.cardfail.2022.10.429
pubmed: 36351494